In the News

Dr. Jack Kavanaugh Named Chairman of Orbsen

Dr. Jack Kavanaugh, an internationally recognized surgeon and businessman who has spearheaded the commercialization of cellular therapies and emerging biotechnology firms has been named Chairman of Orbsen Therapeutics, it was announced today by Dr. Chris Coughlan, Founding Director. “Orbsen Therapeutics has developed cutting edge stem cell technology and is poised to become a leader in the global clinical cell therapy market. The appointment of Dr. Jack Kavanaugh as Chairman, with his international experience, reputation and track record brings us closer to fulfilling the worldwide potential of this remarkable company.”

Orbsen Awarded 6 Million Euros to Test Cell Therapy for Diabetic Kidney Disease

8 June 2015: TheJournal.ie: “NUI Galway spin-out company Orbsen Therapeutics used patented technology to discover the stromal cell therapy, which uses cells purified from healthy donor bone marrow. The four-year research project will see some 48 patients taking part in clinical trials in Galway, Belfast, Birmingham and Bergamo to test the treatment.


NUI Galway Leads Stem Cell Research on Diabetic Kidney Disease

 8 June, 2015:  The Irish Times covered the kick-off of Nephstrom. “The new €6 million EU-funded project, led by NUIG Regenerative Medicine Institute director Prof Timothy O’Brien, will evaluate a type of “next-generation” cell therapy discovered by researchers at the NUIG campus company Orbsen Therapeutics.” Read the complete story at the Irish Times, or learn more about Nephstrom, here.

ORBCEL-M and Nephstrom In the Spotlight

The Nephstrom project and the promise of Orbsen’s stromal cell therapy are up for discussion when RegMedNet interviews Remedi Chair (and Orbsen Director), Professor Timothy O’Brien.

“Funded by a €6-million grant from the European Union Horizon 2020 programme and including many partners, the project is now setting up a stem cell factory with the NHS in Liverpool (UK) and will be conducting a clinical trial of its allogeneic bone marrow stromal cell product (ORBCEL-M) in 48 Type 2 diabetes patients at high risk of developing diabetes-related kidney problems, in the hope of reducing kidney inflammation and improving kidney function.” (more…)

A Day in the Life of Orbsen’s Dr Steve Elliman

Smartfutures interviews Dr. Steve Elliman, head of research at Orbsen Therapeutics, who says no two days are the same at his Galway start-up.

Describe your typical day
My chief function is to manage 11 research scientists in the lab. Another role is grant writing. We’re a start-up so we don’t have big chunks of money from the Government or investors. Also, a lot of my work is taking the data that the guys generate in the lab and looking for the work that is novel and patentable.

Orbsen Cell Therapy Selected for Diabetic Wound Clinical Trial

Pictured L to R: Professor Tim O’Brien, Brian Molloy and Dr Stephen Elliman of Orbsen Therapeutics.

Monday, 12 May 2014 Orbsen Therapeutics’ proprietary stromal cell therapy (Cyndacel-M™) has been selected to be tested in a EU Framework 7 (FP7) funded safety trial for the treatment of non-healing, ulcerating wounds in patients with diabetes. The project known by the acronym “REDDSTAR” (Repair of Diabetic Damage by Stromal Cell Administration) is being co-ordinated by Professor Timothy O’Brien, Dean of Medicine and Director of Ireland’s Regenerative Medicine Institute (REMEDI) at NUI Galway. (more…)

Orbsen Project Receives Industrial Research Fellowship

12 June, 2014: The Minister for Jobs, Enterprise and Innovation, Richard Bruton TD, this week announced the award of funding of over €1.7 million to support twenty new industry-academia partnerships through the Science Foundation Ireland Industry Fellowship Programme, including Dr Daniel O’Toole’s work on the development of a regulatory compliant cell product for Acute Respiratory Distress Syndrome, in partnership with Orbsen Therapeutics.